SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-043679
Filing Date
2017-02-14
Accepted
2017-02-14 17:05:12
Documents
5
Period of Report
2017-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d342585d8k.htm 8-K 16761
2 EX-1.1 d342585dex11.htm EX-1.1 206987
3 EX-5.1 d342585dex51.htm EX-5.1 6772
4 EX-99.1 d342585dex991.htm EX-99.1 8045
5 GRAPHIC g342585g05n13.jpg GRAPHIC 4489
  Complete submission text file 0001193125-17-043679.txt   246258
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 17610191
SIC: 2834 Pharmaceutical Preparations